

Dong-Hua Yang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1748729/publications.pdf>

Version: 2024-02-01

62
papers

2,974
citations

201674

27
h-index

175258

52
g-index

66
all docs

66
docs citations

66
times ranked

4285
citing authors

#	ARTICLE	IF	CITATIONS
1	Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies. <i>Drug Resistance Updates</i> , 2016, 27, 14-29.	14.4	511
2	Modulating ROS to overcome multidrug resistance in cancer. <i>Drug Resistance Updates</i> , 2018, 41, 1-25.	14.4	420
3	Temporally regulated expression of Lin-28 in diverse tissues of the developing mouse. <i>Gene Expression Patterns</i> , 2003, 3, 719-726.	0.8	160
4	Disabled-2 Is Essential for Endodermal Cell Positioning and Structure Formation during Mouse Embryogenesis. <i>Developmental Biology</i> , 2002, 251, 27-44.	2.0	156
5	Musashi-2 (MSI2) supports TGF- β 2 signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 6955-6960.	7.1	120
6	Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters. <i>Cancer Letters</i> , 2018, 421, 186-198.	7.2	96
7	A Novel Potent Anticancer Compound Optimized from a Natural Oridonin Scaffold Induces Apoptosis and Cell Cycle Arrest through the Mitochondrial Pathway. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1449-1468.	6.4	93
8	Molecular events associated with dysplastic morphologic transformation and initiation of ovarian tumorigenicity. <i>Cancer</i> , 2002, 94, 2380-2392.	4.1	71
9	Disabled-2 Is an Epithelial Surface Positioning Gene. <i>Journal of Biological Chemistry</i> , 2007, 282, 13114-13122.	3.4	68
10	Endogenous Sterol Metabolites Regulate Growth of EGFR/KRAS-Dependent Tumors via LXR. <i>Cell Reports</i> , 2015, 12, 1927-1938.	6.4	67
11	Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19. , 2020, 216, 107672.		52
12	Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2019, 25, 3430-3442.	7.0	51
13	Schwann Cell Myelination Requires Integration of Laminin Activities. <i>Journal of Cell Science</i> , 2012, 125, 4609-19.	2.0	49
14	Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters. <i>Scientific Reports</i> , 2016, 6, 25694.	3.3	48
15	Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells. <i>Cellular Physiology and Biochemistry</i> , 2018, 45, 1515-1528.	1.6	48
16	Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. <i>Biochemical Pharmacology</i> , 2014, 89, 52-61.	4.4	47
17	Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. <i>Biochemical Pharmacology</i> , 2018, 158, 274-285.	4.4	47
18	VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters. <i>Frontiers in Pharmacology</i> , 2018, 9, 1236.	3.5	41

#	ARTICLE	IF	CITATIONS
19	Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2. <i>Oncotarget</i> , 2014, 5, 4529-4542.	1.8	41
20	Quercetin overcomes colon cancer cells resistance to chemotherapy by inhibiting solute carrier family 1, member 5 transporter. <i>European Journal of Pharmacology</i> , 2020, 881, 173185.	3.5	40
21	Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells. <i>Molecules</i> , 2016, 21, 1236.	3.8	37
22	Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells. <i>Cancers</i> , 2020, 12, 466.	3.7	37
23	Effect of Y6, an epigallocatechin gallate derivative, on reversing doxorubicin drug resistance in human hepatocellular carcinoma cells. <i>Oncotarget</i> , 2017, 8, 29760-29770.	1.8	31
24	Gaseous signaling molecules and their application in resistant cancer treatment: from invisible to visible. <i>Future Medicinal Chemistry</i> , 2019, 11, 323-336.	2.3	31
25	Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells. <i>Frontiers in Oncology</i> , 2020, 10, 955.	2.8	31
26	Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers. <i>Clinical Cancer Research</i> , 2013, 19, 6633-6643.	7.0	29
27	Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study. <i>Frontiers in Oncology</i> , 2019, 9, 514.	2.8	29
28	Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma. <i>Drug Resistance Updates</i> , 2022, 61, 100822.	14.4	29
29	Disabled-2 Heterozygous Mice Are Predisposed to Endometrial and Ovarian Tumorigenesis and Exhibit Sex-Biased Embryonic Lethality in a p53-Null Background. <i>American Journal of Pathology</i> , 2006, 169, 258-267.	3.8	28
30	Selective reversal of BCRP-mediated MDR by VEGFR-2 inhibitor ZM323881. <i>Biochemical Pharmacology</i> , 2017, 132, 29-37.	4.4	28
31	Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated Multidrug Resistance in Cancer Cells. <i>Frontiers in Oncology</i> , 2019, 9, 313.	2.8	28
32	Tea nanoparticle, a safe and biocompatible nanocarrier, greatly potentiates the anticancer activity of doxorubicin. <i>Oncotarget</i> , 2016, 7, 5877-5891.	1.8	28
33	Renal collecting system growth and function depend upon embryonic $\hat{1}^{31}$ laminin expression. <i>Development (Cambridge)</i> , 2011, 138, 4535-4544.	2.5	27
34	Identification of a Potent Oridonin Analogue for Treatment of Triple-Negative Breast Cancer. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 8157-8178.	6.4	25
35	Overexpression of ABCB1 Transporter Confers Resistance to mTOR Inhibitor WYE-354 in Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1387.	4.1	25
36	Antimicrobial Peptide Reverses ABCB1-Mediated Chemotherapeutic Drug Resistance. <i>Frontiers in Pharmacology</i> , 2020, 11, 1208.	3.5	23

#	ARTICLE	IF	CITATIONS
37	Ontogeny of sulphated glycoconjugate-producing cells in the rat fundic gland. <i>The Histochemical Journal</i> , 1996, 28, 33-43.	0.6	22
38	GSK1904529A, a Potent IGF1R Inhibitor, Reverses MRP1-Mediated Multidrug Resistance. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 3260-3267.	2.6	21
39	BCL-2 expression promotes immunosuppression in chronic lymphocytic leukemia by enhancing regulatory T cell differentiation and cytotoxic T cell exhaustion. <i>Molecular Cancer</i> , 2022, 21, 59.	19.2	21
40	Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4095.	4.1	19
41	Pozotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells. <i>Cancers</i> , 2020, 12, 3249.	3.7	19
42	Immunocytochemistry and in situ hybridization studies of pepsinogen C-producing cells in developing rat fundic glands. <i>Cell and Tissue Research</i> , 1998, 293, 121-131.	2.9	18
43	Reversal of Cancer Multidrug Resistance (MDR) Mediated by ATP-Binding Cassette Transporter G2 (ABCG2) by AZ-628, a RAF Kinase Inhibitor. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 601400.	3.7	18
44	Curcumin reverses doxorubicin resistance in colon cancer cells at the metabolic level. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 201, 114129.	2.8	18
45	A novel approach for relapsed/refractory FLT3mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib. <i>Molecular Cancer</i> , 2022, 21, 66.	19.2	18
46	Reversal Effect of ALK Inhibitor NVP-TAE684 on ABCG2-Overexpressing Cancer Cells. <i>Frontiers in Oncology</i> , 2020, 10, 228.	2.8	15
47	CDK Inhibitors as Sensitizing Agents for Cancer Chemotherapy. , 2019, , 125-149.		12
48	Elimination of <i>Foxo1</i> compensates for <i>Smad2</i> requirement in mouse extraembryonic endoderm development. <i>Developmental Dynamics</i> , 2009, 238, 514-523.	1.8	10
49	Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia. <i>Cancer Letters</i> , 2020, 472, 132-141.	7.2	10
50	Establishment and Characterization of a Novel Multidrug Resistant Human Ovarian Cancer Cell Line With Heterogenous MRP7 Overexpression. <i>Frontiers in Oncology</i> , 2021, 11, 731260.	2.8	6
51	Sulfated Glycosaminoglycans In Guinea Pig Neutrophils Studied by Use of Cationic Colloidal Gold. <i>Journal of Histochemistry and Cytochemistry</i> , 1999, 47, 881-887.	2.5	5
52	Expression of N-acetylglucosamine residues in developing rat fundic gland cells. <i>The Histochemical Journal</i> , 2000, 32, 187-193.	0.6	5
53	The expression of gastric H ⁺ -K ⁺ -ATPase mRNA and protein in developing rat fundic gland. <i>The Histochemical Journal</i> , 2001, 33, 159-166.	0.6	5
54	WBPK Approach in predicting zidovudine pharmacokinetics in preterm neonates. <i>Biopharmaceutics and Drug Disposition</i> , 2019, 40, 341-349.	1.9	5

#	ARTICLE	IF	CITATIONS
55	Sulphated glycosaminoglycans in guinea pig eosinophils studied by means of cationic colloidal gold. <i>The Histochemical Journal</i> , 1998, 30, 687-692.	0.6	4
56	Application of Immunohistochemistry in Basic and Clinical Studies. <i>Methods in Molecular Biology</i> , 2020, 2108, 43-55.	0.9	4
57	Sulfated glycosaminoglycans in guinea pig basophils studied by means of cationic colloidal gold. <i>Histochemistry and Cell Biology</i> , 1998, 109, 189-194.	1.7	3
58	Phenotypic Immunostaining of Mucus-Secreting Cells of Foregut Origin.. <i>Acta Histochemica Et Cytochemica</i> , 1999, 32, 135-140.	1.6	3
59	Identification of new potent anticancer derivatives through simplifying the core structure and modification on their 14- hydroxyl group from oridonin. <i>European Journal of Medicinal Chemistry</i> , 2022, 231, 114155.	5.5	3
60	Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signature. <i>Bosnian Journal of Basic Medical Sciences</i> , 2021, , .	1.0	0
61	Laminin matrix assembly and the mediation of epithelial differentiation. <i>FASEB Journal</i> , 2007, 21, A90.	0.5	0
62	Correction: A novel approach for relapsed/refractory FLT3mut+acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib. <i>Molecular Cancer</i> , 2022, 21, .	19.2	0